LCTA-949

LCTA-949 is an investigational, next-generation radiopharmaceutical developed by Lantheus for the treatment of prostate cancer. It is a targeted alpha therapy (TAT) that combines a small molecule ligand with high affinity for the prostate-specific membrane antigen (PSMA) and the alpha-emitting radioisotope Lead-212 (212Pb). PSMA is highly overexpressed in metastatic castration-resistant prostate cancer (mCRPC) cells, making it an ideal target for delivering cytotoxic radiation. Unlike beta-emitting isotopes like Lutetium-177, Lead-212 emits alpha particles which possess higher linear energy transfer and a shorter path length in tissue, potentially offering superior efficacy in treating small clusters of cancer cells and micrometastases while sparing adjacent healthy organs. LCTA-949 is designed to address the needs of patients who are refractory to or have progressed on existing PSMA-targeted therapies.